2. First line or progressive disease if already treated with any form of therapy, including but not limited to chemotherapy, radiotherapy, local therapy, surgery or immuno-therapy. Patients with HCC who failed sorafenib, with documented PD or AEs that resulted in discontinuance of that agent. Patients with pancreatic cancer (dose escalation only) who have progressed following a gemcitabine based regimen. Subjects failing prior platinum containing regimens are eligible. Gastric cancer subjects that express tumor HER-2 amplification must be treated with trastuzumab prior to enrollment, unless trastuzumab is not available for those indications in a particular country.